Streetbeat News

Regulatory

HIMS

LLY

NVO

Hims & Hers Health Inc (NYSE:HIMS) shares rose after the FDA decided to reconsider its decision on drug compounders selling versions of weight loss drugs. This decision affects Eli Lilly's (NYSE:LLY) and Novo Nordisk's (NYSE:NVO) drugs, which are in short supply.

Portfolio Pulse from Adam Eckert

October 14, 2024 | 4:35 pm

HIMS

Hims & Hers Health shares rose after the FDA announced it would reconsider a decision preventing drug compounders from selling their own versions of weight loss drugs.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 4:32 pm

XPEV

XPeng Inc. (NYSE:XPEV) is experiencing a bullish momentum with a Golden Cross formation and the launch of its P7+ all-electric sedan. Despite past declines, the stock has surpassed key moving averages, indicating potential upside. The P7+ launch is strategically timed amid China's stimulus package and international trade challenges.

Portfolio Pulse from Surbhi Jain

October 14, 2024 | 4:31 pm

NIVF

NewGenIvf Group Ltd. (NASDAQ:NIVF) received a noncompliance notification from Nasdaq for failing to maintain a closing bid price of at least $1 per share for 30 consecutive business days. The company has until April 7 to regain compliance or risk delisting.

Portfolio Pulse from Dylan Berman

October 14, 2024 | 4:30 pm

GOOGL

Google plans to update its third-party policy in November to introduce new penalties for third parties that enable significant or sustained policy violations. This move aims to enhance compliance and ensure better adherence to Google's policies.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 4:06 pm

KO

The African regional bloc is investigating Coca-Cola for alleged anti-competitive practices. This could impact Coca-Cola's operations and market position in Africa.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 3:52 pm

BAYRY

Bayer AG has submitted an application to the European Medicines Agency for the approval of darolutamide, an oral androgen receptor inhibitor, for use in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer. The application is based on positive Phase III ARANOTE trial results.

Portfolio Pulse from Vandana Singh

October 14, 2024 | 3:34 pm

OGI

VFF

Germany is emerging as a leader in the European cannabis market, with significant growth potential due to recent decriminalization. Companies like Village Farms International and Organigram Holdings are focusing on this market, leveraging EU GMP certification for international expansion. Canada faces profitability challenges due to high taxes, while Australia shows promise in non-combustible cannabis products.

Portfolio Pulse from Nicolás Jose Rodriguez

October 14, 2024 | 3:26 pm

BFRI

Biofrontera Inc. has announced the database lock for its Phase 3 study of Ameluz-Photodynamic Therapy in treating superficial basal cell carcinoma. The study's data is now ready for analysis, with interim results expected in November 2024. The final submission to the FDA is targeted for Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 2:31 pm

EIS

FXI

ISRA

China's Foreign Minister expressed willingness to resume exchanges with Israel as the situation eases, according to state media.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 2:26 pm